Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F19%3A00078313" target="_blank" >RIV/00209805:_____/19:00078313 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/19:00112848

Result on the web

<a href="https://www.futuremedicine.com/doi/10.2217/fon-2018-0934?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov" target="_blank" >https://www.futuremedicine.com/doi/10.2217/fon-2018-0934?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/fon-2018-0934" target="_blank" >10.2217/fon-2018-0934</a>

Result language

angličtina

Original language name

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Original language description

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients &amp; methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher&apos;s exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Future Oncology

ISSN

1479-6694

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

17

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

1997-2007

UT code for WoS article

000474879700006

EID of the result in the Scopus database

2-s2.0-85068570739